BRIEF published on 11/09/2026 at 17:50, 2 days 12 hours ago Transgene provides an update on its clinical and financial progress Financial Situation Transgene TG4050 Lung Cancer Myvac®
BRIEF published on 11/09/2026 at 17:50, 2 days 12 hours ago Transgene fait le point sur ses avancées cliniques et financières Situation Financière Transgene TG4050 Cancer Du Poumon Myvac®
PRESS RELEASE published on 11/09/2026 at 17:45, 2 days 12 hours ago Transgene poursuit ses programmes cliniques et fait le point sur sa situation financière au troisième trimestre 2026
BRIEF published on 10/05/2026 at 08:05, 1 month 6 days ago Transgene présente son virus oncolytique innovant au SITC 2026 Biotechnologie Immunothérapie Transgene Virus Oncolytique SITC 2026
BRIEF published on 10/05/2026 at 08:05, 1 month 6 days ago Transgene presents its innovative oncolytic virus at SITC 2026 Biotechnology Immunotherapy Transgene Oncolytic Virus SITC 2026
PRESS RELEASE published on 10/05/2026 at 08:00, 1 month 6 days ago Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026 Transgene to present preclinical data on novel oncolytic virus PoxSTG-EEV at SITC 2026 Annual Meeting in Phoenix, Arizona, November 7, 2026 Preclinical Data Poster Presentation Transgene Oncolytic Virus SITC 2026
PRESS RELEASE published on 10/05/2026 at 08:00, 1 month 6 days ago Transgene présentera un poster sur les données précliniques de son virus oncolytique innovant au SITC 2026 Transgene présentera un poster sur les données précliniques de son virus oncolytique innovant au SITC 2026. Détails du poster et contacts disponibles dans le communiqué de presse Transgene Données Précliniques Virus Oncolytique SITC 2026 Poster
BRIEF published on 09/08/2026 at 07:35, 2 months 3 days ago Transgene and ProBioGen Expand Strategic Collaboration Manufacturing Efficiency Transgene Vaccine Production ProBioGen Biotech Partnership
BRIEF published on 09/08/2026 at 07:35, 2 months 3 days ago Transgene et ProBioGen étendent leur collaboration stratégique Transgene Efficacité De Production ProBioGen Partenariat En Biotechnologie Production De Vaccins
BRIEF published on 09/08/2026 at 07:35, 2 months 3 days ago Transgene et ProBioGen renforcent leur partenariat avec un nouvel accord de licence Partenariat Stratégique Immunothérapie Transgene ProBioGen Lignée Cellulaire
Published on 11/12/2026 at 01:40, 4 hours 32 minutes ago Nexteer Announces First Share Repurchase Programme of Up to US$60 Million
Published on 11/11/2026 at 23:30, 6 hours 42 minutes ago Faraday Copper Reports Third Quarter 2026 Financial Results and Announces Changes to the Board of Directors
Published on 11/11/2026 at 23:05, 7 hours 7 minutes ago Vox Royalty Reports Q3 2026 Results and Declares Quarterly Dividend
Published on 11/11/2026 at 23:00, 7 hours 12 minutes ago CCL Industries Announces Appointment of New Director
Published on 11/11/2026 at 22:30, 7 hours 42 minutes ago 55 North Gold Qualifies for Trading on the OTCQB Venture Market and Launches New Corporate Website
Published on 11/12/2026 at 06:00, 12 minutes ago Biomatter Raises $18M Series A to Scale Its AI-Powered Enzyme Design for Global Industry Leaders
Published on 11/12/2026 at 02:20, 3 hours 51 minutes ago Nanjing Offers a Window into the Yangtze River's Cultural Heritage and Renewal
Published on 11/11/2026 at 19:29, 10 hours 43 minutes ago EQS-Adhoc: Allianz SE: Allianz delivers record nine-month result of 14.1 billion euros and raises 2026 outlook
Published on 11/11/2026 at 18:41, 11 hours 30 minutes ago AUSTRIACARD HOLDINGS AG: 9M 2026 Financial Results
Published on 11/10/2026 at 18:00, 1 day 12 hours ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 1 day 12 hours ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 1 day 12 hours ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 1 day 12 hours ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
